| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d81f79f831e4b8da788ba698be288ec
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_37f4922dfb7777b019e504b885211b8e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_43a72884e25aaecffebe0942132d704f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6f4d86235703b3e2a1cb10b98722d80d |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y306-04013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y306-04013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1137 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 |
| filingDate |
2020-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9091cf4bda97e2da83019786f8329ae
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1c5bb3cc0bf3ee3fabeed1ab63d04c5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7bbf5718bff3b3f52defa88fd7815e1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15cbdb0b8af67ef30ac8cf858bad4206
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_693ad32a6203fcdcd40775815c1554a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_badd80a999dd085a093b8db9f29b2684 |
| publicationDate |
2021-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2021099394-A1 |
| titleOfInvention |
Antisense oligonucleotides and their use for the treatment of cancer |
| abstract |
The present invention concerns the treatment of prostate cancer and particularly castration resistant prostate cancer (CRPC). The Heat Shock Protein Hsp27, a chaperone protein, has been long demonstrated as a driver of Castration Resistance Prostate Cancer (CRPC). In the light of identification of the molecular mechanisms, the inventor determined that the Probable ATP-dependent RNA helicase DDX5 is an interactor of Hsp27 and DDXS's expression is modulated by Hsp27. They confirmed that DDX5 overexpression is correlated to the aggressiveness of the tumor, to the CRPC emergency and to the biochemical recurrence risk. They also developed DDX5 - targeting antisense oligonucleotides for research purpose and clinical application. Thus, the invention relates to an inhibitor of DDX5 wherein said inhibitor reduces the expression and/or activity of DDX5 in a subject in need thereof and targets the gene or the mRNA of DDX5. |
| priorityDate |
2019-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |